Headline

The latest stories from AHA Today.

The Federal Bureau of Investigations, amid one of the largest-ever U.S.-led enforcement actions against a botnet, Aug. 29 announced the successful takedown of QakBot, the botnet infrastructure used by cybercriminals for ransomware, financial fraud and other criminal activity.
The Health and Human Services Office of Inspector General Aug. 28 released a strategic plan to align its audits, evaluations, investigations and enforcement of managed care plans in Medicare Advantage and Medicaid.
In response to an Aug. 24 ruling in the U.S. District Court for the Eastern District of Texas setting aside certain regulations implementing the No Surprises Act’s independent dispute resolution process, the Centers for Medicare & Medicaid Services reiterated its earlier suspension of the IDR…
The Centers for Medicare & Medicaid Services sent to each state letters regarding compliance with federal requirements related to automatic eligibility renewals, known as “ex parte” renewals, under Medicaid and the Children’s Health Insurance Program.
July saw the continued worsening of hospitals’ finances, according to a new Kaufman Hall report.
A three-judge panel in federal court last week partially revived a class action lawsuit against UnitedHealth Group subsidiary United Behavioral Health, reversing an earlier decision from 2020.
AHA Aug. 28 supported the Centers for Medicare & Medicaid Services’ proposal to change how certain forms of noncomprehensive coverage can be marketed and sold.
AHA responded to the Centers for Medicare & Medicaid Services’ calendar year 2024 proposed rule for the home health prospective payment system by voicing its extreme concern with the overall net negative update.
In an Aug. 28 letter to House sponsors, the AHA voiced support for the GOLD Card Act of 2023 (H.R. 4968) that would exempt qualifying providers from prior authorization requirements under Medicare Advantage plans.
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs.